Clinical Research Directory
Browse clinical research sites, groups, and studies.
Yoghurt Supplementation In Critically Ill Adults
Sponsor: All India Institute of Medical Sciences, Bhubaneswar
Summary
This pilot randomized controlled trial tested the feasibility of yoghurt supplementation (400 mL/day for 3 days) in critically ill adults receiving nasogastric feeds. Twelve patients were enrolled, with high adherence and no safety concerns reported. Yoghurt intake was associated with a significant reduction in systemic inflammation markers, particularly the neutrophil-to-lymphocyte ratio (NLR), and modest shifts in gut microbiome composition. Beneficial commensals such as Lactiplantibacillus plantarum and Bifidobacterium adolescentis were enriched, while opportunistic pathogens like Klebsiella pneumoniae and Clostridioides difficile were depleted. Microbial network analysis revealed increased connectivity and stability in the yoghurt group. Overall, yoghurt supplementation was feasible, safe, and showed preliminary biological signals of modulating inflammation and microbial ecology, supporting the rationale for a larger multicentre trial.
Official title: Feasibility and Preliminary Effects of Yoghurt Supplementation on the Gut Microbiome and Systemic Inflammation in Critically Ill Adults: A Pilot Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2021-06-01
Completion Date
2021-08-01
Last Updated
2026-09-10
Healthy Volunteers
No
Conditions
Interventions
Yoghurt
Participants receive standard nasogastric enteral feeding supplemented with 400 mL/day of plain yoghurt (OMFED, Bhubaneswar, India) administered once daily for three consecutive days. The intervention is designed to assess feasibility, safety, and preliminary effects on systemic inflammation and gut microbiome composition in critically ill adults.
Locations (1)
All India Institute of Medical Sciences (AIIMS) Bhubaneswar
Bhubaneswar, Odisha, India